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Early Lethality, Functional NF-kB Activation,
and Increased Sensitivity to TNF-Induced
Cell Death in TRAF2-Deficient Mice
both TNFR complexes. Whereas TRAF2 interacts di-
rectly with TNFR2 (Rothe et al., 1994), it is recruited to
TNFR1 via its interaction with an adaptor protein called
TRADD (TNFR1-associated death domain protein; Hsu
et al., 1995, 1996a). TRAF2 also interacts with CD30
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et al., 1996). The TRAF domain of the TRAF2 protein
is further subdivided into a highly conserved TRAF-C
domain that is required for TRAF2 recruitment to theSummary
receptor and a coiled-coil TRAF-N domain that interacts
with two cellular inhibitors of apoptosis, c-IAP1 andTRAF2 is an intracellular signal-transducing protein
c-IAP2 (Rothe et al., 1995b). With the exception ofrecruited to the TNFR1 and TNFR2 receptors following
TRAF1, the N-terminal region of each TRAF protein con-TNF stimulation. To investigate the physiological role
tains a RING finger structure and multiple zinc fingers,of TRAF2, we generated TRAF2-deficient mice. traf22/2
domains thought to dictate the signals generated by amice appeared normal at birth but became progres-
particular TRAF protein (Rothe et al., 1995a; Cao et al.,sively runted and died prematurely. Atrophy of the thy-
1996; Takeuchi et al., 1996). Deletion of the RING fingermus and spleen and depletion of B cell precursors also
domain of TRAF2results in a truncated, dominant-nega-were observed. Thymocytes and other hematopoietic
tive mutant protein that interferes with the downstreamprogenitors were highly sensitive to TNF-induced cell
signaling induced by stimulation of the TNF receptorsdeath and serum TNF levels were elevated in these
and CD40 (Rothe et al., 1995a).TRAF2-deficient animals. Examination of traf22/2 cells
It has been shown that TRAF2 transduces signalsrevealed a severe reduction in TNF-mediated JNK/
required for TNF-mediated activation of the transcrip-SAPK activation but a mild effect on NF-kB activation.
tion factor NF-kB (Rothe et al., 1995a) and the stress-These results suggest that TRAF2-independent path-
activated protein kinase (SAPK or c-Jun N-terminal ki-ways of NF-kB activation exist and that TRAF2 is re-
nase [JNK]; Liu et al., 1996; Natoli et al., 1997; Reinhardquired for an NF-kB±independent signal that protects
et al., 1997). The precise role of JNK/SAPK in pro-against TNF-induced apoptosis.
grammed cell death is still controversial. Studies using
cells with a targeted disruption of SEK1, a kinase directly
upstream of JNK/SAPK, have demonstrated that thisIntroduction
kinase pathway plays a protective role against various
cytotoxic stimuli (Nishina et al., 1997). It has also beenTumor necrosis factor (TNF) is a multifunctional cytokine
recently established that TNF-mediated NF-kB activa-that plays an important role in the regulation of the im-
tion is important for establishing cellular resistance tomune and inflammatory responses (Fiers, 1991). Exces-
TNF-induced apoptosis (Beg and Baltimore, 1996; Liusive TNF also contributes to pathological conditions
et al., 1996; Van Antwerp et al., 1996; Wang et al., 1996).such as septic shock (Beutler and Cerami, 1988). The
Blockade of NF-kB activation either by knockout of themany actions of TNF are mediated by two cell surface
p65 gene or by overexpressionof thesuperinhibitor IkBareceptors, TNF receptor-1 and TNF receptor-2 (TNFR1
renders cellssensitive toTNF-induced cell death. TRAF2and TNFR2), which are present on most cell types (Tar-
is also required for the recruitment of c-IAP1 and c-IAP2taglia and Goeddel, 1992; Vandenabeele et al., 1995).
to the TNFR complexes (Rothe et al.,1995b). Since theseTNF binding induces receptor aggregation, resulting in
TRAF2 activities are anti-apoptotic in nature, TRAF2the recruitment of a number of cytoplasmic signaling
may play a key role in regulating the well-known pro-proteins to the two distinct TNFR complexes (Rothe et
apoptotic activity of TNF.al., 1994; Hsu et al., 1995, 1996a, 1996b; Rothe et al.,
In this study we used gene targeting to generate a1995b; Shu et al., 1996). One of these signaling proteins,
mutant mouse strain specifically deficient in TRAF2. Sur-TNFR-associated factor-2 (TRAF2), is a component of
prisingly, a lack of TRAF2 leads toembryonic and neona-
tal lethality. In addition, we demonstrate that while§To whom correspondence should be addressed (e-mail: tmak@
TRAF2 is required for the activation of the JNK/SAPKoci.utoronto.ca).
pathway, signaling via NF-kB can occur in the absence‖ Present address: Rigel, Inc., 772 Lucerne Drive, Sunnyvale, Califor-
nia, 94086. of TRAF2. TNF signaling in traf22/2 cells was found to
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Figure 1. Targeted Disruption of the Murine traf2 Gene
(A) A portion of the traf2 endogenous locus containing 6 exons (boxes). (Top) TRAF2 cDNA. The domains encoded by the represented exons
are indicated. The targeting construct (T-TRAF2) was designed to replace part of the two exons that encode the ring finger domain of TRAF2
with a PGK-neo gene cassette. (Bottom) The mutant locus resulting from homologous recombination. An extra BamHI restriction site introduced
by the PGK-neo cassette was used for the diagnosis of homologous recombination.
(B) Southern blot analysis of tail DNA harvested from wild-type, traf21/2, and traf22/2 animals. Tail DNA was digested with BamHI and probed
with the radiolabeled flanking probe (Figure 1A).
(C and D) Western blot analysis of TRAF2 protein expression. Total liver lysate, 800 mg, from wild-type, traf21/2, and traf22/2 mice was subjected
to partial purification using glutathione beads saturated with a GST-TNFR2 fusion protein (Rothe et al., 1994). A sample of beads with GST
protein alone was used as a control. The partially purified lysates were fractionated on a 10% denatured polyacrylamide gel, and the Western
blot was probed with polyclonal antibodies raised against a peptide derived from the TRAF-N domain (C) or a peptide from the TRAF-C
domain of TRAF2 (D).
be defective and could be linked to at least some of the Southern blot analysis (Figure 1B). TRAF2 protein ex-
pression in tissues was determined by affinity purifica-observed mutant phenotypes. The results presented in
this paper clarify the proposed roles of TRAF2 in TNF tion and subsequent Western blot analysis, which dem-
onstrated the absence of intact or truncated TRAF2 insignaling and provide important insights into the under-
lying molecular mechanisms of TNF-mediated cellular traf22/2 animals (Figures 1C and 1D). Initial examination
of the progeny from traf21/2 parents in the 129 3 B6life and death.
background revealed a reduced frequency of traf22/2
births. Of the first 310 live pups examined, only 6.5%Results
were traf22/2. As shown in Table 1, examination of the
embryos from heterozygous traf2 matings revealed aDisruption of TRAF2 in Mice Results in Runtism,
Wasting, and Premature Lethality normal Mendelian ratio of TRAF2 mutants until embry-
onic day 14.5 (E14.5). No developmental or morphologi-To elucidate the function of TRAF2 in vivo, we disrupted
the murine traf2 gene in embryonic stem (ES) cells with cal abnormalities were observed in mutant embryos at
this stage. The frequency of viable traf22/2 offspring in-a targeting vector T-TRAF2 (Figure 1A). Heterozygous
ES cell lines containing a mutated traf2 allele were in- creased when the genetic background was mixed (B6 3
BALB/c, 10.0%), and decreased when the backgroundjected into C57BL/6 (B6) blastocysts and male chimeras
with germline transmission were used to generate was closer to the inbred B6 strain (3.4%). This observa-
tion suggests that the B6 inbred strain may have a ge-traf21/2 animals. Heterozygous animals were further
backcrossed to B6 mice and at the same time were netic defect that interacts with the null mutation of
TRAF2 to produce increased lethality.interbred to obtain homozygosity. Homologous recom-
bination and genotype screening were confirmed by Regardless of strain background, viable traf22/2 mice
TNF-Induced Cell Death in TRAF2-Deficient Mice
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Table 1. Genotypic Analyses of the Progeny from TRAF2 Heterozygous Intercrosses
Number of the Genotypes
Percentage
Stage 1/1 1/2 2/2 Total 2/2
E12.5 6 14 11 31 35%
E13.5 8 13 9 30 30%
E14.5 22 47 25 94 27%
E16.5 12 17 4 33 12%
E17.5 12 20 7 39 18%
Newborn pups 8 28 4 40 10%
Live-born pups 98 192 20 310 6%
Timed breedings were set up between traf21/2 males and females (129 3 B6 background). E14.5 was defined as 14.5 days after fertilization.
Tails of newborns were collected at the time of birth; tails of live-born pups were collected about 3 weeks after birth or at the time of death.
The genotypes were determined primarily by PCR analyses, as described in Experimental Procedures. Early genotyping was confirmed by
Southern blot analysis.
appeared normal at birth but became smaller than their TRAF2-Deficient Hematopoietic Progenitors
Are Sensitive to TNF-Induced Cell Deathlittermates after 2±3 days. traf22/2 mutants developed
normally in their four extremities, but their body trunks To investigate the defects of hematopoietic lineages
in traf22/2 animals, cells of the bone marrow, thymus,were devoid of fat deposits and reduced in muscle mass
compared to those of their wild-type littermates. The spleen, and lymph nodes were harvested and analyzed
by cell counts and flow cytometry. No obvious abnor-mutant animals became more runted with time, and pre-
mature mortality was observed, with the incidence of malities were observed in the erythroid or myeloid lin-
eages. Thymocytes from traf22/2 animals were reduceddeath peaking at the age of 10±14 days. At the time of
death, the body weights of mutant animals ranged from in total cell number and were devoid of CD41CD81 (dou-
ble-positive [DP]) cells as the mutant mice approached20% to 50% of normal controls. Only a small percentage
of traf22/2 mice survived longer than 3 weeks, and these the terminal stage (data not shown). However, thymo-
cytes derived from younger animals or fetal thymic organwere typically either from a small litter or from the hybrid
background. Most organs of traf22/2 animals, while pro- cultures showed a profile of surface markers similar
to the wild type (data not shown), indicating normalportionally smaller than those of control littermates, re-
vealed no gross developmental abnormalities. The ex- thymocyte development in the absence of TRAF2. In
bone marrow, B cell precursors (B2201CD432) fromceptions were the thymus and spleen, which were
extremely atrophic. Microscopic examination of tissues traf22/2 animals were reduced compared to normal con-
trols (Figure 2), but a complete blockade of B cell devel-of traf22/2 animals revealed lymphoid depletion in the
thymus and spleen and lack of secondary germinal opment was not observed.
The depletion of lymphocytes in traf22/2 animals couldcenters in spleen and lymph nodes. Examination of peri-
pheral blood cells from mutant animals showed lympho- be due to a pathological up-regulation of cytotoxic fac-
tors such as steroid hormones or to an intrinsic defectpenia of both T and B lymphocytes and relative granulo-
cytosis, but normal erythrocyte counts. of cell survival, or both. Because TRAF2 is involved in
Figure 2. B Cell Development in the Bone
Marrow of traf22/2 Survivors
Bone marrow cells were harvested from a
9-day-old traf22/2 mutant and its littermates
and were subjected to flow cytometric analy-
sis as described in Experimental Procedures.
The numbers shown in each quadrant repre-
sent the percentage of total viable cells.
Immunity
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TNF signaling, which, through TNFR1, includes both
pro-apoptotic and anti-apoptotic pathways, we set out
to determine the exact role of TRAF2 in these pathways.
Thymocytes from traf22/2 and control animals were cul-
tured at 378C and treated with the cytotoxic agents
mouse TNFa (mTNFa), anti-Fas antibody, or dexametha-
sone. After 20 hr, cells were harvested and triple-stained
with CD4, CD8, and 7-aminoactinomycin D (7-AAD). As
shown in Figures 3A and 3B, relative to untreated con-
trols, DP cells from traf22/2 mice were more sensitive
to TNF-induced cell death than were cells from either
traf21/1 or traf21/2 mice. In contrast, the viability of DP
cells of all genotypes was reduced to a similar degree by
Fas signaling or dexamethasone treatment. Comparison
of untreated traf21/1 and traf22/2 cells revealed in-
creased spontaneous apoptosis of traf22/2 DP thymo-
cytes over a 20 hr period of culture at 378C (Figure 3B),
even though the starting populations of both genotypes
contained the same percentage of viable DP cells. Simi-
lar results were obtained when the rate of cell death of
fetal thymocytes harvested from thymic organ cultures
from E14.5 embryos was examined (data not shown).
Other TRAF2-deficient hematopoietic precursors also
were tested for their sensitivity to TNF-induced death.
In vitro colony-forming assays were performed using
fetal liver cells from E14.5 embryos in the presence or
absence of 10 ng/ml mTNFa. When plated in the ab-
sence of TNFa, erythroid (CFU-E and CFU-E/MEG) and
myeloid (CFU-G, CFU-GM, and CFU-MAC) colonies
from traf22/2 fetal livers developed normally. In the
presence of TNFa, however, very few or no colonies
developed from traf22/2 fetal livers, while colonies from
traf21/1 or traf21/2 fetal livers were only mildly sup-
pressed (Table 2).
To assess further the viability of TRAF2-deficient he-
matopoietic cells in vivo, we performed adoptive trans-
fer experiments by injecting E14.5 embryonic liver cells
into lethally irradiated B6 mice. Wild-type and traf21/2
fetal liver cells were capable of reconstituting the hema-
topoietic system, and 100% survival rate (6 of 6 for 1/1 Figure 3. The Sensitivity of TRAF2-Deficient Thymocytes to Murine
and 19 of 19 for 1/2) was observed in the recipients TNF
when examined 3 months after transfer. In contrast, of (A) Survival of CD41CD81 (DP) thymocytes after various treatments.
the irradiated B6 hosts receiving traf22/2 fetal liver cells, Thymocytes from a relatively healthy 2-week-old traf22/2 mouse and
its littermates were harvested and cultured at 378C for 20 hr inonly 45% (5 of 11) survived past the first 3 weeks after
the absence or presence of the indicated stimuli. After treatment,transfer. The surviving traf22/2 fetal liver recipients were
thymocytes were triple-stained with CD4, CD8, and 7-AAD. Viablefurther examined 3 months after transfer, and poorly
DP cells (negative 7-AAD stain) from individual treatments were
reconstituted hematopoiesis including anemia and lym- plotted as percentagesof the total viable DP cells from the untreated
phopenia was observed (data not shown). controls of the respective genotypes. Each treatment group is com-
posed of three bars with standard errors, representing traf21/1,
traf21/2, and traf22/2 DP thymocytes.
(B) Flow cytometric analysis of viable DP thymocytes. traf21/1 orDefective TNF Signaling in TRAF2-Deficient
traf22/2 thymocytes untreated or treated with 10 ng/ml mTNF wereMice Is Mediated by TNFR1
triple-stained as above and gated on cells with negative 7-AADTo dissect the TNF signaling defects in traf22/2 thymo-
stain. The number at the top right of each panel is the percentage
cytes, human TNF (which interacts with mouse TNFR1, of total cells that were viable DP cells.
but not mouse TNFR2) and receptor-specific agonist
antibodies against TNFR1 or TNFR2 were examined in
the presence of the protein synthesis inhibitor cyclohexi- TRAF2 plays an important role in protecting thymocytes
from TNF-induced apoptosis and that in the absence ofmide. Thymocytes from traf22/2 mice were more sensi-
tive than traf21/2 or traf21/1 cells to human TNF± or TRAF2, cells become susceptible to TNF-induced cell
death mediated through TNFR1.anti-TNFR1±induced cell death (Figure 4). Anti-TNFR2
treatment did not kill cells of any genotype. Similar re- To determine whether TNF was involved in the re-
duced viability of traf22/2 mice, TNF levels in sera fromsults were obtained in experiments using fetal thymo-
cytes (data not shown). These observations indicate that animals aged 2±3 weeks were examined. Whereas TNF
TNF-Induced Cell Death in TRAF2-Deficient Mice
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Table 2. In Vitro Colony-Forming Assay of Fetal Liver Cells
Genotype Treatment E E/MEG G MAC GM Multi TOTAL
1/1 2TNF 36.0 6 1.2 8.5 6 2.3 39.0 6 6.3 82.0 6 8.7 37.3 6 4.0 4.5 6 1.6 206.3 6 11.1
1TNF 34.5 6 5.8 15.3 6 6.0 12.8 6 1.9 79.8 6 4.3 29.3 6 7.4 4.5 6 1.7 176.0 6 16.9
1/2 2TNF 32.6 6 4.1 8.4 6 1.6 38.6 6 4.4 80.0 6 5.9 20.8 6 2.4 3.1 6 0.5 186.5 6 14.9
1TNF 31.8 6 3.6 9.3 6 1.6 11.1 6 1.4 60.2 6 9.0 13.6 6 2.7 1.7 6 0.4 125.6 6 17.4
2/2 2TNF 22.8 6 5.0 14.3 6 4.6 11.0 6 3.2 110.0 6 5.8 20.3 6 5.4 4.3 6 1.0 182.5 6 22.6
1TNF 0.0 6 0.0 0.25 6 0.25 1.25 6 0.75 5.5 6 2.8 0.5 6 0.5 0.0 6 0.0 7.5 6 3.5
Fetal liver cells of E14.5 embryos were plated in media facilitating the growth and differentiation of hematopoietic colonies in the absence or
presence of 10 ng/ml recombinant mTNFa, as described in Experimental Procedures. Numbers in each column represent colonies of specific
or mixed lineages identified per 105 fetal liver cells. Only colonies with more than 50 cells were counted.
E, erythroid colony; E/MEG, erythroid and megakaryocytic colony; G, granulocytic colony; MAC, macrophage colony; GM, granulocytic and
macrophage colony; multi, multilineage colony (containing more than two lineages).
could not be detected in sera from wild-type and hetero- in the absence of TRAF2, several independent TRAF2-
deficient and control embryonic fibroblast (EF) lineszygous animals, TRAF2-deficient animals showed clearly
were derived. The EF cell lines were stimulated withdetectable levels of serum TNF (Figure 5). The elevation
mTNF for various periods, and NF-kB activation wasof serum TNF could be either an indirect consequence
determined by gel mobility shift assays. Surprisingly,of illness or, alternatively, a direct effect of the TRAF2
near-normal NF-kB activation was clearly demonstrabledeficiency that results in dysregulated TNF synthesis.
in traf22/2 EF cells, albeit with delayed kinetics (FigureIn any case, this result demonstrates in vivo the signifi-
6A). By 90 min after mTNF treatment, the proportion ofcance of the supersensitivity of TRAF2-deficient cells
activated NF-kB in traf22/2 EF cells was equivalent toto TNF.
the proportion present in control EF cells. Similar delays
were observed in other traf22/2 EF lines as well as in
TRAF2-deficient thymocytes (data not shown). The com-TRAF2 Is Required for TNF-Mediated JNK/SAPK
position of activated NF-kB in traf22/2 cells was exam-Activation and the Early Phase
ined using specific antibodies to different NF-kB familyof the NF-kB Response
members, including p65 (RelA), p50, and c-Rel (FigureTRAF2 has been implicated in the TNF-mediated activa-
6B). No obvious differences were observed in the su-tion of the NF-kB and JNK/SAPK pathways. To test
pershift pattern between wild-type and mutantcells (Fig-whether the activation of these pathways is abrogated
ure 6B).
The activation of JNK/SAPK by mTNF was also exam-
ined in traf22/2 EF cells. The activation of JNK/SAPK in
wild-type cells peaked at about 10±15 min after mTNF
treatment (Figure 6C). However, cells lacking TRAF2
showed greatly reduced JNK/SAPK activity. This defect
in JNK/SAPK activation was specific to the TNF signal-
ing pathway, because other stress signals, such as an-
isomycin (Figure 6C), ultraviolet irradiation, and heat
Figure 4. TNFR1 versus TNFR2 Signaling in the TNF Hypersensitiv-
ity of TRAF2-Deficient Cells
Thymocytes from a 2-week-old traf22/2 mutant and its littermates
were cultured in the presence of cycloheximide (C) and either mTNF,
human TNF (hTNF), murine TNFR1 agonist antibody (anti-TNFR1),
Figure 5. Serum TNF Levels in Surviving TRAF2-Deficient Miceor TNFR2 agonist antibody (anti-TNFR2). After incubation for 20 hr,
cells were triple-stained with CD4, CD8, and 7-AAD. The results Serum TNF concentrations were determined in three pairs of traf22/2
mice and their littermate controls (1/1, 2/2; CC9, CC11; and WL,are shown as viable DP cells remaining after various composite
treatments, expressed as a percentage of the viable DP cells surviv- WS), as described in Experimental Procedures. Micewere sacrificed
at the age of 2±3 weeks. nd, not detectable.ing cycloheximide treatment alone for each genotype.
Immunity
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Figure 7. TNF Cytotoxicity of traf2-/- and traf21/1 EF Cells
TRAF2-deficient and wild-type EFs were treated with mTNFa (10
ng/ml) andcycloheximide (0.25 mg/ml) for the indicated time periods.
Cells viability was determined by trypan blue exclusion. Two inde-
pendent cell lines of each genotype are shown.
dramatically reduced (20%±40% viable) in the presence
of mTNFa for 8 hr (Beg and Baltimore, 1996). In compari-
son, we examined the sensitivity of traf22/2 EFs to
mTNFa (10 or 100 ng/ml), and after 24 hr of treatment
cell viability remained approximately 90%. This indi-
cated that there are differential sensitivities to TNF
among different TRAF2-deficient cell types. We then
treated TRAF2-deficient and control EFs with mTNFa
(10 ng/ ml) and cycloheximide (0.25 mg/ml) and analyzed
cell viability after 6 or 24 hr. While wild-type EFs were
not affected under this condition, TRAF2-deficient EFs
started to die as early as 6 hr after treatment, and only
Figure 6. TNF-Mediated NF-kB andJNK/SAPK Activation in TRAF2- 15%±40% of the mutant cells survived by 24 hr after
Deficient Fibroblasts treatment (Figure 7). Taken together, these results sug-
(A) TRAF2-deficient EF cells and wild-type controls were incubated gest that TRAF2 is important in mediating a protective
with mTNF (10 ng/ml) for the indicated time periods. Nuclear extracts signal parallel but complementary to NF-kB-mediated
(10 mg) harvested at each time point were incubated with a radiola-
protection.beled probe containing NF-kB binding sites, and NF-kB activation
was determined using a gel mobility shift assay as described in
Experimental Procedures. Discussion
(B) TRAF2-deficient fibroblasts and wild-type cells were treated with
mTNF for 30 min. Nuclear extracts (10 mg) were incubated with Ex vivo experiments have demonstrated that TRAF2
specific antibodies against different members of the NF-kB family
plays an important role in transducing signals elicitedfor 30 min before the addition of the radiolabeled probe and gel
by multiple members of the TNFR superfamily, includingmobility shift assay.
TNFR1 (Hsu et al., 1996a; Liu et al., 1996; Shu et al.,(C) TRAF2-deficient fibroblasts and wild-type cells were incubated
with TNF for various times as indicated, or with anisomycin (aniso), 1996), TNFR2 and CD40 (Rothe et al., 1995a), CD30
cycloheximide (cyclo), or cycloheximide plus TNF for 30 min. Protein (Ansieau et al., 1996; Gedrich et al., 1996; Lee et al.,
lysates from individual samples were immunoprecipitated with a 1996; Aizawa et al., 1997; Boucher et al., 1997; Duckett
JNK/SAPK-specific antibody, and kinase activity was assayed using
et al., 1997; Tsitsikov et al., 1997), and herpesvirus entrya GST-c-Jun fusion protein as the substrate, as described in Experi-
mediator (Montgomery et al., 1996; Hsu et al., 1997;mental Procedures.
Marsters et al., 1997). In the present investigation, we
used gene targeting to show in vivo that TRAF2 defi-
ciency produces mice that fail to thrive, are runted, showshock (data not shown), were still able to activate JNK/
SAPK in traf22/2 cells. Finally, we examined c-IAP1 and lymphopenia, and die prematurely. This severe pheno-
type contrasts sharply with the milder phenotypes ofc-IAP2 and found that they were expressed at equivalent
levels in TRAF2-deficient and wild-type cells (data not TNFR1 and TNFR2 knockout mice (Pfeffer et al., 1993;
Erickson et al., 1994), which generally are in good healthshown).
in a pathogen-free environment. Mice with targeted dis-
ruptions of CD40 and CD30 have also shown limitedTRAF2-Deficient EF Cells Are More Sensitive
to TNF-Induced Cell Death in the phenotypes with defects specific to the immune system
(Kawabe et al., 1994; Amakawa et al., 1996). However,Presence of Cycloheximide
Wild-type EF cells are resistant to TNF treatment, while mice deficient in TRAF3, a protein homologous to
TRAF2, are also runted, exhibit lymphopenia, and die atthe viability of NF-kB p652/2 (RelA-deficient) EFs are
TNF-Induced Cell Death in TRAF2-Deficient Mice
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an early postnatal stage (Xu et al., 1996). Such a severe with anti-TNF antibody injection, 105 pups were born
and 10 (9.5%) were identified as traf22/2. Thus, therephenotype cannot be explained by the findings to date
was a clear but incomplete rescue of the TRAF2 mutantthat TRAF3 specifically associates with CD40 and the
embryos by TNF inhibition. This rescue effect was notEpstein-Barr virus latent membrane protein 1 (Hu et al.,
enhanced by increasing the frequency of the injections1994; Cheng et al., 1995; Mosialos et al., 1995; Sato et
(data not shown). Mild improvement but incomplete res-al., 1995; Devergne et al., 1996; Izumi et al., 1997). We
cue was also observed in the live-born TRAF2 pupsconclude that TRAF2 and TRAF3 are probably involved
regularly injected with the anti-TNF antibody (data notin important transduction pathways, other than TNF sig-
shown). However, the small number of overall traf22/2naling, that remain to be identified.
live-born survivors is a limitation; in future studies, theThe lymphoid depletion common to TRAF2- and
role of TNF toxicity in traf22/2 mutants could be ad-TRAF3-deficient mice could be either the result of an
dressed more completely by generation of TRAF2 andintrinsic defect in cell survival or simply a consequence
TNF double-knockout animals.of the up-regulation of cytotoxic factors such as steroid
This study also shows that the defective TNF signalinghormones. Since TRAF3-deficient fetal liver cells were
in TRAF2-deficient cells that leads to increased cellable to reconstitute all hematopoietic lineages in lethally
death is mediated by TNFR1. Previous studies haveirradiated recipients, it was concluded that TRAF3 is not
shown that TRADD, an adaptor protein that binds di-essential for hematopoietic cell survival (Xu et al., 1996).
rectly to the death domain of TNFR1, can transduceHowever, our examinations of TRAF2-deficient cells re-
signals both for apoptosis and for NF-kB activation (Hsuvealed the existence of intrinsic defects in the response
et al., 1995). TRADD achieves these responses by re-of these cells to TNF. Thymocytes and other hematopoi-
cruiting either FADD (Fas-associated death domain pro-etic progenitors from traf22/2 animals and embryos were
tein) or TRAF2 to the TNFR1 complex, thereby signalinghighly sensitive to TNF-induced cell death. Adoptive
apoptosis or NF-kB activation, respectively (Hsu et al.,transfer experiments showed that traf22/2 fetal liver cells
1996a). Activated NF-kB in turn generates a protectivewere unable to reconstitute the hematopoietic compart-
signal against TNF-induced apoptosis (Beg and Balti-ment of lethally irradiated mice. In addition, serum TNF
more, 1996; Liu et al., 1996; Van Antwerp et al., 1996;was readily detectable in the TRAF2 mutant animals.
Wang et al., 1996). Thus, in the absence of TRAF2, TNFThese results suggest that both intrinsic cell defects
signaling through TNFR1 is mediated primarily by aand the elevation of a cytotoxic factor contribute to
TRADD±FADD interaction, which leads to apoptosis.the phenotype of the TRAF2 knockout mouse, and that
This signal shunting suggests that in normal cells, thereTRAF2 and TRAF3 play distinctly different roles in intra-
exists an important balance of signaling initiated by TNFcellular signaling.
and that TRAF2 is essential for the protective signalingSome aspects of the TRAF2 mutant phenotype are
pathway.
consistent with the toxicity induced by excessive levels
Examination of TNF-induced NF-kB activation in TRAF2-
of TNF (Beutler and Cerami, 1988; Probert et al., 1993).
deficient cells revealed unexpectedly normal levels of
The TRAF2-deficient mice are devoid of fat deposits
this transcription factor complex, although its kinetics
and muscle mass, and wasting starts shortly after birth of activation were delayed. Thus, we have shown that
and progresses until the time of death. In addition, thy- NF-kB can be activated by TNF even in the absence of
mocytes and B cell precursors are progressively de- TRAF2. Three of six TRAF proteins characterized to date
pleted. However, we did not observe in TRAF2-deficient (TRAF2, TRAF5, and TRAF6) are able to mediate the
mice the histopathological changes, including vascular activation of NF-kB (Rothe et al., 1995a; Cao et al., 1996;
thrombosis and extensive tissue necrosis, reported in Ishida et al., 1996a, 1996b; Nakano et al., 1996; Aizawa
transgenic mice that express high levels (100±1300 et al., 1997). TRAF5, a protein similar to TRAF2, is widely
pg/ml in serum) of human TNF (Probert et al., 1993). expressed in various tissues and is also used by multiple
Indeed, comparatively moderate serum TNF levels (20± members of the TNF receptor superfamily, including
50 pg/ml) were detected in TRAF2-deficient animals. It CD40, CD30, and the lymphotoxin-b receptor (Nakano
is possible that the persistently detectable serum TNF et al., 1996). It is possible that TRAF5 can substitute for
is derived from dysregulation of TNF synthesis and se- TRAF2 in NF-kB activation induced by TNF or other
cretion in animals lacking TRAF2. Further investigation TNF-related factor signals, consistent with the ability of
into the molecular mechanisms regulating TNF gene TRAF5 to interact with TRADD (D. V. G., unpublished
expression and processing will help address this issue. data). Alternatively, RIP (receptor-interacting protein),
Could the complete phenotypes of TRAF2-deficient another signaling protein that interacts with TRADD,
mutants be explained by TNF toxicity? Because the em- TNFR1, and TRAF2, may be more important than TRAF2
bryonic lethality is the prominent feature of traf22/2 mu- in activating NF-kB in vivo (Stanger et al., 1995; Hsu
tants in the genetic background close to the inbred B6 et al., 1996b). Consistent with this hypothesis, a RIP-
strain, we attempted to rescue the mutant embryos by deficient mutant Jurkat cell line is defective in TNF-
TNF inhibition using a specific anti-TNF antibody. We induced NF-kB activation but fully susceptible to Fas-
injected anti-TNF monoclonal antibody (8 mg/g body induced apoptosis (Ting et al., 1996).
weight) derived from hamster (Genzyme)or control ham- An obvious question remaining to be addressed is the
ster immunoglobulins into the peritoneum of pregnant molecular mechanism(s) by which TRAF2 transmits its
females from heterozygous intercrosses on day 11.5 of protective signal. One possibility is that the transmission
gestation. These heterozygous animals were generated occurs through preformed complexes between TRAF2
by repeated backcrossing to B6 at least three times. Of and c-IAP1 and c-IAP2 (Rothe et al. 1995b; Shu et al.,
eight litters from the control injection, 56 pups were born 1996). The c-IAPs have been proposed to signal an anti-
apoptotic function, but the precise mechanism remainsand only 1 (1.8%) was traf22/2. From 15 females treated
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Western Blot Analysisunknown. TRAF5, despite its ability to activate NF-kB,
Total liver lysates from traf21/1, traf21/-, and traf2-/- littermates werecannot interact with or recruit cIAPs to either TNF recep-
homogenized in lysis buffer containing 50 mM Tris-Cl (pH 7.4), 100tor (D. V. G., unpublished data). This leaves open a possi-
mM NaCl, 1% Nonidet P-40 (NP-40), 2 mM EDTA, 10% glycerol,
ble specific role for TRAF2 in the recruitment of c-IAPs and the protease inhibitors aprotinin (1 mg/ml), leupeptin (1 mg/ml),
in TNF-mediated cell protection. Alternatively, TRAF2- and phenylmethylsulfonyl fluoride (PMSF, 10 mM/ml). Next, 800 mg
lysate from each genotype was partially affinity purified for TRAF2mediated protection may occur through the TNF-induced
using glutathione beads saturated with a fusion protein of glutathi-JNK/SAPK pathway, which is greatly reduced in TRAF2-
one S-transferase (GST)±TNFR2 (Rothe et al., 1994). After fivedeficient cells. Recent studies have dissociated the acti-
washes in lysis buffer containing 250 mM NaCl, the protein samplesvation of JNK/SAPK by TNF from the induction of
were fractionated by 10% SDS±polyacrylamide gel electrophoresis
apoptosis (Liu et al., 1996; Natoli et al., 1997; Reinhard et and blotted onto a nitrocellulose membrane. The Western blot was
al., 1997), although the phenotype of the SEK1 knockout probed with a polyclonal antibody against a specific polypeptide
derived from the TRAF2±TRAF-N domain or with an antibody againstmouse suggests that this pathway may be involved in
a polypeptide from the TRAF2±TRAF-C domain. The blot was thenthe regulation of apoptosis (Nishina et al. 1997).
developed using an enhanced chemiluminescence system ac-One intriguing hypothesis possibly accounting for a
cording to the manufacturer's instructions (Amersham).protective effect of TRAF2 suggests that ªsurvival ef-
fectorº genes that have yet to be identified may be tran- Flow Cytometric Analysis of TRAF2-Deficient
scriptionally activated by NF-kB. In this scenario, Hematopoietic Cells
TRAF2-deficient cells undergo TNF-induced apoptosis Single-cell suspensions were prepared from lymphoid organs, in-
cluding thymus and bone marrow, as previously described (Ama-because of delayed activation of NF-kB. It is possible
kawa et al., 1996). For antibodydetection in each cytometric analysisthat the early phase of NF-kB activation is crucial to
5 3 105 cells were used The antibodies used in this study, includinginduce the expression of the survival effectors properly.
phycoerythrin (PE)±conjugated anti-CD8a and anti-B220antibodies,
Alternatively, perhaps TRAF2 induces an NF-kB±inde- and fluorescein isothiocyanate (FITC)±conjugated anti-CD4, anti-
pendent protective signal against TNF-induced apoptosis. CD43, and anti-IgM antibodies were obtained from Pharmingen.
Such a signal might then collaborate with NF-kB at the After staining, fluorescent signals onthe cell surfaces were analyzed
with a FACScan flow cytometer (Becton Dickinson) and CellQuesttranscriptional level or interact directly with the survival
software.effectors. Further identification of these downstream
cell survival transducers will provide an important blue-
Thymocyte Death Assayprint of the molecular mechanism that antagonizes the
Freshly isolated thymocytes were cultured in RPMI medium con-
cell death machinery. taining 5% fetal bovine serum and were plated at 5 3 105 cells/ml
in each well of a 24-well dish. Various cytotoxic agents were added,
including dexamethasone 1 mM, mTNF 10 ng/ml, anti-Fas antibody
Experimental Procedures (Jo-2 clone, a gift from S. Nagata) 1 mg/ml, human TNF 10 ng/ml,
cycloheximide 50 mg/ml, cycloheximide plus mTNF, cycloheximide
Generation of traf22/2 Mice by Gene Targeting plus human TNF, cycloheximide plus anti-TNFR1 agonist antibody
A genomic DNA clone for traf2 was isolated by screening a 129/Sv/J (1:300 dilution), and cycloheximide plus anti-TNFR2 agonist anti-
mouse genomic DNA library using a probe derived from the 59 end body (1:300 dilution). After 20 hr of incubation at 378C in 5% CO2,
of the mouse traf2 cDNA. The cDNA region encoding the TRAF2 the cells were harvested, stained with PE-CD8a, FITC-CD4, and
ring finger domain was mapped to two exons separated by a 1.7 7-AAD (used at 1 mg/ml, Sigma), and analyzed with a FACSscan
kb intron (Figure 1A). The targeting construct T-TRAF2 was made cytometer and CellQuest software as previously described (Nishina
by replacing the entire ring finger coding region and the intervening et al., 1997). 7-AAD is a vital dye which enters dead cells after loss
intron with the PGK-neo gene cassette in the reverse orientation to of membrane integrity. It allows quantitation of dead and viable cells
the endogenous traf2 gene. Linearized T-TRAF2 was then by the FL-3 channel on a FACScan cytometer and can be used in
transfected into ES cells (E14 clone, derived from 129/Ola mouse combination with FITC-conjugated (channel FL-1) and PE-conju-
embryos) by electroporation. Neomycin-resistant ES clones were gated (channel FL-2) antibodies against specific cell surface mark-
selected by 300 mg/ml G418 (Sigma) in Dulbecco's modified Eagle's ers (Schmid et al., 1994). Viable double-positive (CD41CD81) cells
medium supplemented with 15% fetal bovine serum and leukemia were displayedon a dotplot gated on thymocytes negatively stained
inhibitory factor. Homologous recombinants were identified by poly- by 7-AAD. Individual treatments were measured in triplicate, and at
merase chain reaction (PCR) using a traf2-specific primer down- least three independent experiments were performed. Induction of
stream of the targeting construct (59-ATA CAC TTG CAC AGA CAT thymocyte apoptosis was confirmed by DNA laddering as previously
ACA TGC AAG CAA-39) and a primer in the PGK-neo gene cassette described (Amakawa et al., 1996). Parallel tryptan-blue vital staining
(59-AAG CGC ATG CTC CAG ACT GCC TTG GGA A-39). Genomic was also performed.
DNA was isolated from PCR-positive clones and analyzed by South-
ern blot hybridization using the flanking probe (Figure 1A) and a In Vitro Hematopoietic Colony-Forming Assay
probe specific for the neomycin-resistance gene. The flanking probe The in vitro colony-forming assay was performed as previously de-
was a radiolabeled 162 bp StuI±PstI fragment downstream of the scribed (Karasuyama and Melchers, 1988). In brief, freshly isolated
targeting construct. ES clones confirmed for homologous recombi- fetal liver cells from E14.5 embryos were plated at a density of 105
nation and a single PGK-neo insertion were injected into C57BL/6J cells/ml in a 3 cm dish. Cells were cultured in the Iscove's modified
blastocysts, which were then transferred into CD1 pseudopregnant Dulbecco's medium containing 1.2% methylcellulose, 4% fetal bo-
foster mothers. The resulting male chimeras were backcrossed with vine serum, 0.5% serum fraction V, 100 mg/ml transferrin, and 10
C56BL/6J females, and germline transmission in F1 traf21/2 mice mg/ml insulin. The culture medium was supplemented with the fol-
was verified by Southern blot analysis. Heterozygous mice were lowing cytokines: IL-1b (1 ng/ml, a gift from R. Shaw and J. J.
interbred to obtain traf22/2 mice. Genotyping of the F2 mice was Mermod, Glaxo Research Institute, Geneva); IL-3 (15 U/ml, condi-
performed by PCR on tail genomic DNA and verified by Southern tioned medium of myeloma cells expressing murine IL-3, Karasu-
blot analysis. The PCR primers for wild-type traf2 alleles were yama and Melchers, 1988); IL-11 (30 ng/ml, recombinant human IL-
59-GGC TGA GCA GGC AGT GCT CAG AGA TTC-39 and 59- CCT 11, Genetics Institute, Boston, MA); c-Kit ligand (3% v/v, conditioned
CAT TCC GTT ACC AGT GTT ACA GA-39. The primer pairs for the medium of Chinese hamster ovary cells expressing murine c-Kit
mutant alleles were 59-AAG CGC ATG CTC CAG ACT GCC TTG GGA ligand, a gift from D. Donaldson, Genetics Institute, Boston); and
erythropoietin (1 U/ml). Plates treated with TNF received 10 ng/mlA-39 and 59-CCT CAT TCC GTT ACC AGT GTT ACA GA-39.
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recombinant mTNFa (Genzyme). Erythroid colonies were counted EF Death Assay
EF cells were grown in Dulbecco's modified Eagle's medium supple-after 7 days, and granulocytic, macrophage, and megakaryocytic
colonies were counted after 12 days. mented with 5% fetal bovine serum. Cells were plated at 2 3 105
cells/ well of a six-well dish 2 days before the treatment. Recombi-
nant mTNFa (Genzyme) was used at 10 ng/ml, and cycloheximideMeasurement of Serum TNF
was used at 250 ng/ml. The cells were incubated with medium only,Whole blood was collected from traf22/2 mutants and control lit-
mTNFa alone, or mTNFa plus cycloheximide for 0, 6, or 24 hr. Thetermates and centrifuged in a Microtainer serum separator (Becton
cells were then trypsinized and viability was determined by trypanDickinson), and the sera were stored at 2708C. Measurement of
blue exclusion.TNF was performed in duplicate on serum samples diluted 1:2 or
1:4 using an mTNFa enzyme-linked immunosorbent assay kit (Gen-
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Gel Mobility Shift Assay
Nuclear extracts were harvested according to protocols previously Received July 24, 1997; revised September 19, 1997.
described (Pfeffer et al., 1993). In brief, 2 3 106 cells, either untreated
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